These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2624600)

  • 1. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Fiedler VB; Perzborn E; Seuter F; Rosentreter U; Böshagen H
    Arzneimittelforschung; 1989 Dec; 39(12):1527-30. PubMed ID: 2624600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Seuter F; Perzborn E; Rosentreter U; Böshagen H; Fiedler VB
    Arzneimittelforschung; 1989 Dec; 39(12):1525-7. PubMed ID: 2624599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of a novel thromboxane antagonist, BAY-U3405, on canine myocardial damage after coronary artery occlusion and reperfusion.
    Fiedler VB; Perzborn E; Seuter F
    Pharmacotherapy; 1991; 11(1):77-84. PubMed ID: 2020615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer.
    Rosentreter U; Böshagen H; Seuter F; Perzborn E; Fiedler VB
    Arzneimittelforschung; 1989 Dec; 39(12):1519-21. PubMed ID: 2624597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
    Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K
    Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
    Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
    Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of BAY U 3405, a new thromboxane antagonist, on sudden death in rabbits.
    Seuter F; Perzborn E; Fiedler VB; Rosentreter U; Böshagen H
    J Lipid Mediat; 1991; 3(3):283-8. PubMed ID: 1773029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ
    Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Action of the novel selective thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid on vascular smooth muscle preparations.
    Perzborn E; Seuter F; Fiedler VB; Rosentreter U; Böshagen H
    Arzneimittelforschung; 1989 Dec; 39(12):1522-5. PubMed ID: 2624598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Bay U 3405, a new thromboxane antagonist, on collagen-induced thromboembolism in rabbits.
    Seuter F; Perzborn E; Fiedler VB
    Stroke; 1990 Dec; 21(12 Suppl):IV146-8. PubMed ID: 2260139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thrombus formation by endothelin-1 in canine models of arterial thrombosis.
    Leadley RJ; Humphrey WR; Erickson LA; Shebuski RJ
    Thromb Haemost; 1995 Dec; 74(6):1583-90. PubMed ID: 8772241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
    White BP; Sullivan AT; Lumley P
    Thromb Haemost; 1994 Mar; 71(3):366-74. PubMed ID: 8029802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.